Intellia Therapeutics, Inc. (NTLA) intrinsic value & 10-year financials
Intellia Therapeutics, Inc. (NTLA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 17.0% a year to $67.7M, with an average return on invested capital of -42.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $11.42
- Market cap
- $1.2B
- Revenue (FY2025)
- $67.7M
- Revenue growth (10-yr CAGR)
- 17.0%
- ROIC (10-yr avg)
- -42.3%
- Free cash flow (FY2025)
- -$395.9M
NTLA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $67.7M | -$412.7M | -$3.81 | -$395.9M | -651.7% | -60.6% |
| FY2024 | $57.9M | -$519.0M | -$5.25 | -$354.7M | -923.1% | -57.9% |
| FY2023 | $36.3M | -$481.2M | -$5.42 | -$408.1M | -1420.5% | -55.1% |
| FY2022 | $52.1M | -$474.2M | -$6.16 | -$346.8M | -879.0% | -52.5% |
| FY2021 | $33.1M | -$267.9M | -$3.78 | -$237.8M | -810.4% | -38.8% |
| FY2020 | $58.0M | -$134.2M | -$2.40 | -$53.5M | -235.5% | -42.9% |
| FY2019 | $43.1M | -$99.5M | — | -$110.0M | -246.8% | -44.2% |
| FY2018 | $30.4M | -$85.3M | — | -$67.6M | -298.6% | -29.5% |
| FY2017 | $26.1M | -$67.5M | — | -$75.4M | -266.3% | -26.5% |
| FY2016 | $16.5M | -$31.6M | — | $29.9M | -195.2% | -15.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Intellia Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 17.0% annually over the past decade.
Intellia Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.3% ROIC.
Intellia Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Intellia Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-126.55 per share.